EUDA Health Holdings Limited Announces Shenzhen Inno’s Approval Under Shenzhen Key Industry R&D Program

EUDA Health Holdings Limited announced that its subsidiary, Shenzhen Inno Immune Co., Ltd., has received approval under the 2025 Shenzhen Key Industry R&D Program for its TCR-T cell therapy development project. This program, supervised by the Shenzhen Science and Technology Innovation Bureau, aims to support critical technological innovation. Shenzhen Inno's project, focusing on TCR-T cell therapies for solid tumors, is expected to receive funding of up to approximately US$434,688. The project involves developing HLA-restricted epitopes, utilizing an AI-driven antigen screening platform, enhancing cellular engineering for T-cell therapies, and establishing an integrated research and clinical framework. This development aligns with EUDA's strategy to expand access to advanced treatment modalities and provides the company with continued exposure to next-generation T-cell therapies within its distribution scope in Malaysia through its subsidiary CK Health Plus Sdn Bhd, with treatments conducted in China.